


## **SUPPLEMENTARY FIGURES**




**Supplementary Figure 1. SLC family of genes that were overexpressed in PDAC.** \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001.




**Supplementary Figure 2. SLC family of genes that were downregulated in PDAC.** \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001.



Supplementary Figure 3. Overall survival curve of SLC proteins overexpressing in PDAC. \*p < 0.05; \*\*p < 0.01.



Supplementary Figure 4. Overall survival curve of SLC proteins down-regulated in PDAC. \*p < 0.05; \*\*p < 0.01.



Supplementary Figure 5. Correlation of SLC protein expression with progression-free survival and disease characteristics of PDAC patients. (A) Disease-free survival curve of patients with differential SLC protein expression and corresponding progression-free survival. (B) Association of SLC41A1 expression with tumour stage progression. (C) Association of SLC41A1 expression with medical history of diabetes. \*p < 0.05; \*p < 0.01.